Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triazinate
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Triazinate is a synthetic dihydrotriazine derivative with antineoplastic properties. It acts as an antifolate agent related to methotrexate and inhibits the enzyme dihydrofolate reductase (DHFR), leading to decreased production of tetrahydrofolate and interference with thymidylate synthesis. Unlike methotrexate, triazinate is not converted to polyglutamate forms. It also inhibits folate transport and may be selectively toxic to methotrexate-resistant tumor cells[1][2].
- Brand names
- Baker's Antifol solubleBaker's AntifolanteBakers AntifolBakers Antifolate
- Other names
- triazinatealpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-triazin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on triazinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triazinate.